( ation to publicly update any forward-lo...)Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18,Health

Forward-looking statements in this press release should be evaluated together with the many uncertainties that affect Merck's business, particularly those mentioned in the risk factors and cautionary statements in Item 1A of Merck's Form 10-K for the year ended Dec. 31, 2006, and in its periodic reports on Form 10-Q and Form 8-K, which the Company incorporates by reference.

GARDASIL(R) is a registered trademark of Merck & Co., Inc., Whitehouse Station, N.J., U.S.A.

Prescribing information and patient product information for GARDASIL(R) is attached and is also available at www.gardasil.com. -0-

MERCK & CO., INC.

Whitehouse Station, NJ 08889, USA                              9682301

----------------------------------------------------------------------


GARDASIL(R)

(Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant

Vaccine)


DESCRIPTION


    GARDASIL* is a non-infectious recombinant, quadrivalent vaccine

prepared from the highly purified virus-like particles (VLPs) of the

major capsid (L1) protein of HPV Types 6, 11, 16, and 18. The L1

proteins are produced by separate fermentations in recombinant

Saccharomyces cerevisiae and self-assembled into VLPs. The

fermentation process involves growth of S. cerevisiae on

chemically-defined fermentation media which include vitamins, amino

acids, mineral salts, and carbohydrates. The VLPs are released from

the yeast cells by cell disruption and purified by a series of

chemical and physical methods. The purified VLPs are adsorbed on

preformed aluminum-containing adjuvant (amorphous aluminum

hydroxyphosphate sulfate). The quadrivalent HPV VLP vaccine is a

sterile liquid suspension that is prepared by combining the adsorbed

VLPs of each HPV type and additional amounts of the

aluminum-containing adjuvant and the final purification buf
'"/>




Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 
Related medicine technology :

1. New Phase 3 Study Published in The Lancet Evaluates Efficacy and
Safety of Prezista/Ritonavir vs. Kaletra as Part of HIV Combination
Therapy in Treatment-Experienced Adults With HIV
2. New Proof of Genisteins Efficacy and Safety for Osteopenia and
Osteoporosis Published in Annals of Internal Medicine
3. Bio-Matrix Scientifics Dr. ONeill Sees University of Pittsburghs
Published Study on Culture Blood-Forming Stem Cells from Human Fat
Tissue as Supporting Near Term Benefits of Banking Adipose (Fat)
Derived Stem Cells
4. Interim Analysis of Crinone Pregnancy Study to Be Published in
American Society for Reproductive Medicine Journal
5. VIVUS Announces Abstract Published at American Diabetes Association
Scientific Sessions
6. Anacor Identifies a Novel Mechanism for Its Lead Anti-Fungal Drug,
AN2690; Findings Published in Science
7. Research on New Treatment for Neglected Disease Published in The
New England Journal of Medicine
8. Landmark Study Published in the New England Journal of Medicine
Shows Important Benefits of Eprodisate (KIACTA) Treatment for
Patients with Amyloid A (AA) Amyloidosis
9. Newly Published Data from Large Study Support Cardiovascular Safety
of Avandia (Rosiglitazone Maleate)
10. Javelin Pharmaceuticals Phase II Rylomine (Intranasal Morphine)
Data Published in Pain Medicine
11. Newly Published Data Demonstrates Superiority of Cipralex Over
Duloxetine for Acute Treatment of Depression